

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone

Upfront quadruplets combining daratumumab (D), bortezomib (V), an immunomodulatory drug, such as thalidomide (T) or lenalidomide (R), and dexamethasone (d) for newly diagnosed (ND) multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT) were approved by regulatory agencies based on the superiority of D-VTd and D-VRd over the standard-of-care triplets VTd and VRd, respectively.^{1,2} By study design, patients enrolled in both these trials received a single ASCT, which remains the gold standard strategy for transplant-eligible (TE) ND-MM in the latest National Comprehensive Cancer Network (NCCN) and European Hematology Association-European Myeloma Network (EHA-EMN) guidelines.³ In the EHA-EMN guidelines, European experts suggest considering tandem (or double) ASCT for patients with high-risk cytogenetic abnormalities (HRCA), an option supported by post-hoc analyses of randomized studies showing the superiority of tandem over single ASCT in this setting.^{4,5} However, those studies included only bortezomib-based induction triplets not incorporating an anti-CD38 monoclonal antibody. Data informing the use of tandem ASCT outside clinical studies in the current real-world era of highly active quadruplet induction therapies are lacking. In addition, no Italian registry has gathered any useful information that would allow this question to be addressed.

To bridge this gap, on behalf of the GIMEMA Multiple Myeloma Working Party, we conducted a retrospective, multicenter, nationwide online survey aimed at detailing the physician's choice and selection criteria of tandem ASCT for TE NDMM patients who received D-VTd induction therapy. Assessment of efficacy outcomes of tandem ASCT was out of the scope of our analysis. In Italy, D-VTd received regulatory approval on November 24th, 2021. The survey was conducted in compliance with Italian ethical standards and regulations, and collected data from January 1st, 2022, to June 30th, 2024. Out of 110 affiliated hematological centers invited to participate, 66 (60%) completed the survey (*Online Supplementary Table S1*) and their data were included in this analysis.

Over the study period, 2,784 NDMM patients were considered to be TE and received standard-of-care D-VTd induction therapy (Figure 1): 960 (34%) in 2022, 1,165 (42%) in 2023, and 659 (24%) in the first six months of 2024 (Table 1). Baseline fluorescence *in situ* hybridization (FISH)

results were available in 2,616 (94%) patients who were mostly screened for del(17p), t(4;14) and t(14;16), while gain/amp(1q21) was assessed in a minority of them. Overall, 756 (29%) patients carried ≥ 1 HRCA, and 693 (25%) patients had Revised International Staging System (R-ISS) stage 3 disease. At data cut-off (April 24th, 2025), 2,551 (92%) patients underwent either single (71%) or tandem (29%) ASCT (Figure 1). There were 658 patients (36%) receiving single ASCT in 2022, 758 (42%) in 2023, and 394 (22%) from January to June 2024. Tandem ASCT was pre-planned in 987 patients (35%) and was actually received by 741 (75%) of these, including 257 (26%) patients in 2022, 346 (35%) in 2023, and 138 (14%) from January to June 2024 (Table 1). Physician's choice of tandem ASCT was based on multiple and frequently co-occurring criteria, the most common being the presence at baseline of ≥ 1 HRCA (85%) and/or extramedullary disease combined or not with circulating tumor cells (67%) (Table 2). Advanced disease stage at




Figure 1. Disposition of transplant-eligible newly diagnosed multiple myeloma patients across the survey. ASCT: autologous stem cell transplantation; D-VTd: daratumumab, bortezomib, thalidomide, dexamethasone; pts: patients; TE NDMM: transplant-eligible newly diagnosed multiple myeloma.

diagnosis and suboptimal response to first ASCT were criteria for choice of tandem ASCT in 36% and 35% of patients, respectively. Overall, 246 (25%) patients in the pre-planned tandem ASCT group did not undergo a second ASCT, 89 (9%) of these due to inadequate peripheral blood stem cell collection and the remaining 157 patients due to other causes, including treatment-related adverse events, patients' refusal, and disease progression. At data-cut off, 1,066 (38%) patients had completed D-VTd consolidation therapy, and 2,136 (76.7%) had started lenalidomide maintenance therapy (Figure 1).

Over the first 30 months following the regulatory approval of D-VTd, tandem ASCT was selected by treating physicians at 66 hematological centers as the most appropriate option for 35% of patients who started induction therapy. Key selection factors were the presence at baseline of HRMM, most frequently HRCA, and a suboptimal response to first ASCT. Interestingly, drivers of tandem ASCT selection in this real-world setting were aligned with those of several ongoing phase III studies incorporating quadruplets. In part 1 of the GMMG-HD7 trial comparing VRd *versus* isatuximab (Isa)-VRd as induction therapy before ASCT, tandem ASCT was recommended for patients with HRCA or failing complete response (CR) after first transplantation.⁶ In addition, data from our real-world survey revealed that 75% of patients actually received tandem ASCT, a rate consistent with data from clinical studies of triplet- and quadruplet-based induction therapies.^{4,5,7,8} A suboptimal yield of CD34⁺ cells (<4x10⁶/Kg) was reported in 9% of patients. Although in the real-world setting there is some heterogeneity in institutional policies and among patients, this rate is within the range reported in other studies of D-VTd and systematic reviews of D-based quadruplets.⁹

Several large retrospective registry-based studies enrolling more than 35,000 patients were published in 2025 and compared single *versus* tandem ASCT.^{10,11} Overall, survival outcomes with single ASCT were inferior to those with tandem ASCT, which was likely to mostly benefit patients failing to achieve CR after first ASCT^{10,11} and to overcome HRCA,¹² although this latter finding was not consistent across all patients.¹¹ In one of these studies, 26% of patients received tandem ASCT between 2017 and 2021,¹⁰ a rate that is in line with the findings of our survey that was conducted in the years 2022-2024. Although results from these analyses are informative, it is worth noting that most of the patients were accrued before the introduction of quadruplets including D or Isa combined with VRd. In addition, the inherent selection bias of patients who actually received tandem ASCT might have contributed to the benefits of this therapy being over-estimated. Quadruplet therapies are now standard-of-care for both TE and TI patients with NDMM. In the transplant setting, their combined use with high-dose melphalan has increased the rates of CR up to approximately 90% and

of MRD negativity in the range between 60% and >80%, ultimately resulting in meaningful improvements in PFS and OS.^{1,2} Although the superiority of quadruplets over triplet-based therapies has been established across subgroups of patients at different risk, the greatest benefit was seen for patients at standard risk. In particular, outcomes in patients with ≥ 2 HRCA (some of which were included in the recent genomic re-definition of HRMM proposed by the International Myeloma Society / International Myeloma Working Group¹³) continue to be unsatisfactory even today. As such, in the PERSEUS study the PFS hazard ratios for patients at standard risk and with ≥ 1 HRCA were 0.35 ($P < 0.0001$) and 0.59 ($P = 0.044$), respectively, while in those with ≥ 2 HRCA including gain or amp(1q21), the hazard ratio was 0.73 ($P = 0.39$).¹⁴ The results from a post-hoc analysis of the phase II GRIFFIN and MASTER studies are in line with these data. In the GRIFFIN study of D-RVd and subsequent D-R maintenance, the estimated 4-year PFS rate was 53.5% and sustained MRD negativity lasting ≥ 1 year was 31%.¹⁵ Similarly, the corresponding values in the MASTER study of D-carfilzomib (K)-Rd as induction therapy before, and consolidation after ASCT were 52%

Table 1. Disposition of transplant-eligible newly diagnosed multiple myeloma patients per year.

Patients' disposition, N	2022	2023	2024*	Total
Patients with TE NDMM treated with D-VTd induction	960	1,165	659	2,784
Patients treated with D-VTd induction who received single ASCT	658	758	394	1,810
Patients treated with D-VTd induction who received tandem ASCT	257	346	138	741
Patients treated with D-VTd induction who received single or tandem ASCT	915	1,104	532	2,551

*From January 1st, 2024, to June 30th, 2024. ASCT: autologous stem-cell transplantation; D-VTd: daratumumab, bortezomib, thalidomide, dexamethasone; N: number; TE NDMM: transplant-eligible newly diagnosed multiple myeloma.

Table 2. Criteria of choice of tandem autologous stem cell transplantation in participating centers.

Criteria of choice of tandem ASCT	Centers Total N=66
Presence at baseline of HRCA, N (%)	56 (85)
EMD and/or circulating plasma cells, N (%)	44 (67)
Advanced disease stage at baseline, N (%)*	24 (36)
Suboptimal response to first ASCT, N (%)**	23 (35)
Others, N (%)	9 (14)

ASCT: autologous stem-cell transplantation; EMD: extramedullary disease; HRCA: high-risk chromosomal abnormalities, including del(17p), t(4;14), t(14;16), gain/amp(1q21), and del(1p); N: number. *Defined as International Staging System and/or Revised International Staging stage 3 disease. **Defined as less than very good partial response.

(at 3 years) and 50%.¹⁵ Patients with ≥ 2 HRCA constitute a subgroup with still high unmet clinical need for whom there may still be room for improved outcomes beyond the use of quadruplets and single ASCT.

Further treatment intensification by incorporating D-KRD induction and consolidation into tandem ASCT followed by D-R maintenance for up to two years was explored in the phase II IFM 2018-04 study for patients with HR NDMM, 60% of whom carried ≥ 2 HRCA.⁷ The rates of CR and MRD negativity following the second ASCT were 81% and 97%, respectively, and the 30-month PFS and OS rates were 80% and 91%, respectively. In the phase III MIDAS study, TE NDMM patients with MRD positivity (10^{-5} sensitivity) after Isa-KRD induction therapy were randomized to subsequent consolidation with single ASCT and 2 additional cycles of Isa-KRD or double ASCT.⁸ At the time of reporting, the rate of post-consolidation MRD negativity at a sensitivity of 10^{-6} was 32% in the tandem ASCT group and 40% in the single ASCT-Isa-KRD group, but data on sustained MRD negativity and PFS were not mature.

This survey provides real-world insights into clinical practice patterns in Italy in the management of TE NDMM patients in the contemporary era of quadruplets. According to physician's choice, tandem ASCT was the most appropriate option for approximately one-third of TE NDMM patients treated with standard-of-care D-VTd induction; a real-world finding that had not been available before. Candidates to tandem ASCT were mostly selected based on the presence of HR characteristics at baseline, reflecting the European guidelines that recommend tandem ASCT as the only treatment modification option for HRMM. Consistently with other studies, the second ASCT was actually received by 75% of patients, confirming the feasibility of this procedure even after an intensified induction therapy. Whether tandem ASCT might be an alternative to, or even part of, an intensified treatment program including extended induction, consolidation and maintenance therapy for patients with HRMM is currently under evaluation in ongoing studies.

We acknowledge that the retrospective nature of the survey represents a limitation of our analysis. However, the strengths of this survey lie in the number of centers participating, being representative of the broader medical community. In addition, the survey reflects real-world behavior, assuring generalizability of results. Finally, although we cannot exclude possible selection bias, patients' characteristics were likely to be representative of the general population.

Authors

Carmine Liberatore,^{1,2} Alfonso Piciocchi,³ Donatella Vincelli,⁴ Katia Mancuso,^{5,6} Maurizio Musso,⁷ Gabriele Buda,⁸ Daniele Derudas,⁹ Laura Pavan,¹⁰ Angelo Belotti,¹¹ Angela Rago,¹² Laura Paris,¹³ Roberto Mina,^{14,15}

Concetta Conticello,¹⁶ Elena Rossi,¹⁷ Cristina Skert,¹⁸ Fabrizio Accardi,¹⁹ Cristina Clissa,²⁰ Elisabetta Antonioli,²¹ Francesca Farina,²² Anna Furlan,²³ Luca Franceschini,²⁴ Silvia Mangiacavalli,²⁵ Claudia Cellini,²⁶ Sara Aquino,²⁷ Lorenzo De Paoli,²⁸ Nicola Giuliani,²⁹ Francesco Vassallo,³⁰ Valeria Sargentini,³ Stefano Soddu,³ Sara Bringhen,¹⁴ Massimo Gentile,^{31,32} Giuseppe Mele,³³ Francesca Patriarca,³⁴ Sonia Morè,^{35,36} Francesca Fazio,³⁷ Pellegrino Musto,^{38,39} Francesco Di Raimondo¹⁶ and Michele Cavo⁶

¹Department of Medicine and Aging Sciences, "G d'Annunzio" University, Chieti; ²Hematology Unit, Pescara Hospital, Pescara; ³GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome; ⁴Department of Hemato-Oncology and Radiotherapy, Hematology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria; ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna; ⁶Department of Medical and Surgical Sciences, University of Bologna, Bologna; ⁷Onco-Hematology Unit and TMO U.O.C., Department of Oncology, La Maddalena, Palermo; ⁸Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa; ⁹Department of Hematology, Businco Hospital, Cagliari; ¹⁰Hematology Unit, Department of Medicine, University of Padova, Padova; ¹¹Department of Hematology, ASST Spedali Civili di Brescia, Brescia; ¹²UOSD Ematologia ASL Roma 1, Rome; ¹³Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo; ¹⁴Division of Hematology 1, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino; ¹⁵Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino; ¹⁶Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania; ¹⁷Section of Hematology, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome; ¹⁸UOC Ematologia, Ospedale dell'Angelo, Mestre; ¹⁹Onco-Hematology Unit, Azienda Ospedaliera Riunita (AOR) Villa Sofia-Vincenzo Cervello, Palermo; ²⁰UOC di Ematologia, DAI Medico-Generale, AOUI Verona, Verona; ²¹Hematology Unit, Careggi University Hospital, Firenze; ²²Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Milan; ²³Division of Hematology, Ospedale Ca' Foncello, Treviso; ²⁴Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome; ²⁵Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia; ²⁶Santa Maria delle Croci Hospital, Ravenna; ²⁷Hematology and Cellular Therapy Center, IRCCS Ospedale Policlinico San Martino, Genova; ²⁸UO Ematologia, Ospedale Sant' Andrea, Vercelli; ²⁹University of Parma and Hematology Unit, AOU, Parma; ³⁰Division of Hematology, Ospedale Santa Croce e Carle, Cuneo; ³¹Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza; ³²Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende; ³³Hematology Unit, "Perrino" Hospital, Brindisi; ³⁴Hematology, DMED, University of Udine, University Hospital of Friuli Centrale, Udine; ³⁵Hematology Unit, AOU delle Marche, Ancona; ³⁶Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona; ³⁷Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome; ³⁸Department of Precision and Regenerative Medicine and Ionian Area "Aldo Moro" University School of Medicine, Bari and ³⁹Unit of Hematology and Stem Cell Transplantation AOUC Policlinico, Bari, Italy

Correspondence:

M. CAVO - michele.cavo@unibo.it

<https://doi.org/10.3324/haematol.2025.300238>

Received: November 17, 2025.

Accepted: February 27, 2026.

Early view: March 19, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Disclosures

No conflicts of interest to disclose.

Contributions

CL and MC wrote the manuscript. AP performed survey analysis. All other authors read and agreed to the final version of the manuscript for publication.

Data-sharing statement

Original data are available in anonymous form upon request to the corresponding author.

References

1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394(10192):29-38.
2. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024;390(4):301-313.
3. Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. *Nat Rev Clin Oncol*. 2025;22(9):680-700.
4. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. *Lancet Haematol*. 2020;7(6):e456-e468.
5. Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of post autologous hematopoietic cell transplantation strategies in the upfront treatment of multiple myeloma. *J Clin Oncol*. 2020;38(15_suppl):8506.
6. Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. *J Clin Oncol*. 2025;43(11):1279-1288.
7. Touzeau C, Perrot A, Hulin C, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. *Blood*. 2024;143(20):2029-2036.
8. Perrot A, Lambert J, Hulin C, et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. *N Engl J Med*. 2025;393(5):425-437.
9. Liberatore C, Perini T, Passeri C, et al. Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma. *Haematologica*. 2023;108(12):3502-3505.
10. Iacobelli S, Schönland S, Koster L, et al. Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transplant*. 2025;60(10):1361-1368.
11. Grieb N, Oeser A, Ferle M, et al. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. *Bone Marrow Transplant*. 2025;60(3):335-345.
12. Gagelmann N, Eikema DJ, Koster L, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019;25(11):2134-2142.
13. Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. *J Clin Oncol*. 2025;43(24):2739-2751.
14. Dimopoulos MA, Sonneveld P, Rodriguez-Otero P, et al. Daratumumab + bortezomib / lenalidomide / dexamethasone (D-VRd) in transplant-eligible (TE) patients with newly diagnosed myeloma (NDMM): analysis of the phase 3 PERSEUS study based on high-risk cytogenetic abnormalities (HRCAs). *Clin Lymphoma Myeloma Leuk*. 2024; 24(Suppl 1):S547-S548.
15. Callander NS, Silbermann R, Kaufman JL, et al. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. *Blood Cancer J*. 2024;14(1):69.